AB1145 GENDER, AGE AND PULMONARY FUNCTION IN DOMINICAN PATIENTS WITH RHEUMATIC DISEASES
Background: Interstitial lung disease (ILD) is a frequent entity in patients with rheumatic diseases, worsening the prognosis of those who suffer it (1). Previous studies have used the GAP (Gender, Age, Pulmonary function) model stage system to determine mortality at 1, 2 and 3 years (2). For stage I is 5.6% the first year, 10.9% second and 16.3% the third. GAP II has a mortality of 16.2%, 29.9% y 42.1% for the first, second and third year. For stage III, 39.2%, 62.1% and 76.8% respectively (3) Objectives: To perform GAP model stage system in Dominican patients with Interstitial Lung Disease (ILD) related to Rheumatic Diseases (RD). Methods: This is an observational, cross sectional study, with 42 patients who presented ILD related to RD. The GAP model stage system was determined by using demographic variables and pulmonary function tests such as spirometry and lung diffusion capacity (DLCO). Results: 36 patients were female; the median age was 45±12 years. The mean value for Forced Vital Capacity (FVC) was 72%, Forced expiratory volume in 1 second (FEV1) 73%, and the ratio FEV1/FVC 99%. The DLCO mean value was 66±23 ml/min/mmHg. 35 patients (83.3%) were in stage I, 7 patients (16.6%) in stage II and none in stage III. The statistical significant variables were the time of diagnosis of the RD (p=0.013); with 4.9 years for those in stage I and 10.8 years for stage II; the time of the diagnosis of the ILD (p=0.003) with 2.1 years for patients in stage I and 4.8 years for stage II and smoking (p=0.063). Conclusions: These findings suggest that the GAP model system is an useful tool to stage patients with interstitial lung disease related to rheumatic diseases. It can also help us make changes in treatment based on the stage. Special attention must be paid to those with a longer time of diagnosis of the RD, time of diagnosis of the ILD and/or smoking. Background: Osteoarthritis (OA) is the most prevalent joint disease and the leading cause of disability from 60 years onwards. In fact, 14,8% of the Spanish population has OA.
Objectives:
This study aimed to analyze the indications and average doses prescribed in the treatment of knee osteoarthritis in Primary Care in Spain. Methods: The EMARTRO study was designed as an observational, multicenter, transversal study to compare probability of suffering a comorbidities based on presence of symptomatic knee OA visited by GPs. Sociodemographic, anthropometric, clinical parameters and clinical variables of interest were recorded. The prescribed medications and doses indicated in syntomatic knee OA were analyzed in patients included in the EMARTRO study. Results: A total of 1173 patients were included, of whom 646 had knee OA. Patients with OA had a mean (SD) BMI of 30.9 (5.1), systolic blood pressure 132.8 (14.5) and diastolic blood pressure 77.9 (9.1) mm Hg. They also had a mean of 4.3 (1.9) comorbidities, the most frequent were hypertension 358 (62.2%), dyslipidemia 336 (58.3%), diabetes mellitus II 126 (21.9%), and gastroesophageal reflux 110 (19.1%). As for the symptomatology, the patients presented a mean (SD) pain in Huskisson's VAS of 65.18 (15.27) mm and algofunctional Lequesne score of 11.35 (4.86). Patients were treated with a mean of 2,2 medications. The 45.5% of osteoarthritic patients were treated as monotherapy, 35.5% were taking 2 medications for osteoarthritis, 15.3% 3 and 3.7% 4 or more medications. It should be noted, taking into account the high levels of pain, that 15% of the patients did not receive any treatment. Regarding prescribed medications for knee OA, 378 (58.2%) patients were treated with paracetamol at a mean daily dose (SD) of 1,150.5 (1,815.5) mg; 232 (35.9%) received NSAIDs, with metamizole being the most prescribed at doses 1,092 (538) mg, ibuprofen at doses 1,136 (528,8) mg and naproxen at doses 941,8 (238,5) mg. Next, 131 (20.3%) patients were treated with opioids, tramadol being the most frequent at doses 102.7 (49.7) mg; 87 (13.3%) with SYSADOA being chondroitin sulphate the most frequent at doses 758.7 (247.7) mg. Finally, 87 (13.3%) of the patients were treated with COX-2, mainly with etoricoxib at doses of 69.3 (27.1) mg. Conclusions: Although the patients presented many concomitant pathologies, it is frequent to approach osteoarthritis in polytherapy. In addition, despite the high symptomatology, patients are treated primarily with a mild analgesic such as paracetamol at doses lower than those recommended. It is paradoxical the high prescription of NSAIDs in a population with a high prevalence of cardiovascular and gastrointestinal pathologies as well as an increase in the prescription of opioids. 
